Janus kinase (JAK) Inhibitors Competitive landscape report 2022 by DelveInsight 1
Janus kinase (JAK) Inhibitors Competitive landscape
Janus kinase (JAK) Inhibitors pipeline constitutes 40+ key companies continuously working towards developing 45+ Janus kinase (JAK) Inhibitors treatment therapies, analyzes DelveInsight

Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted treatment and are the first oral option to compare favorably to existing biologic disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib, baricitinib and upadacitinib are the first 3 JAK inhibitors to become commercially available in the field and are the core focus of this review.

 

DelveInsights, “Janus kinase (JAK) Inhibitors Competitive landscape, 2022” report provides comprehensive insights about 40+ companies and Janus kinase (JAK) Inhibitors drugs in Janus kinase (JAK) Inhibitors inhibitors Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the Janus kinase (JAK) Inhibitors Pipeline report, click here: Janus kinase (JAK) Inhibitors Competitive landscape

 

Key Takeaways from the Janus kinase (JAK) Inhibitors Competitive landscape report:

  • Leading Janus kinase (JAK) Inhibitors Companies working in the market are Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co. and Others.
  • Key Janus kinase (JAK) Inhibitors therapies in various stages of development include RINVOQ, Ritlecitinib, Momelotinib, Ruxolitinib, Filgotinib, Itacitinib, Ivarmacitinib, Golidocitinib, Nezulcitinib, CPL409116, TD 5202, ATI- 2138 and Others.
  • In March 2022, AbbVie announced that the US Food and Drug Administration has approved RINVOQ for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.

 

DelveInsight’s Janus kinase (JAK) Inhibitors Report covers around 45+ products under different phases of clinical development like

  • Assessment by Janus kinase (JAK) Inhibitors Product Type
  • Assessment by Stage and Product Type of Janus kinase (JAK) Inhibitors
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of Janus kinase (JAK) Inhibitors
  • Assessment by Janus kinase (JAK) Inhibitors Molecule Type
  • Assessment by Stage and Molecule Type of Janus kinase (JAK) Inhibitors

 

Emerging Janus kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:

Some of the Janus kinase (JAK) Inhibitors therapies are Filgotinib, TD 8236 and Many Others.

 

Further  Janus kinase (JAK) Inhibitors product details are provided in the report. Download the  Janus kinase (JAK) Inhibitors Pipeline report to learn more about the emerging Janus kinase (JAK) Inhibitors therapies at: Janus kinase (JAK) Inhibitors drugs and medication 

 

Key companies in the Janus kinase (JAK) Inhibitors Therapeutics Market:

Some of the Janus kinase (JAK) Inhibitors Companies working in the market are Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co. and Others.

 

Request for Sample PDF Report to know in detail about the recent developments  and advancements in Janus kinase (JAK) Inhibitor clinical trials Phases of Janus kinase (JAK) Inhibitor Drugs in Pipeline

 

Table of Content (TOC)

1. Janus kinase (JAK) Inhibitor Pipeline Report Introduction

2. Janus kinase (JAK) Inhibitor Pipeline Report Executive Summary

3. Janus kinase (JAK) Inhibitor Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Janus kinase (JAK) Inhibitor Clinical Trial Therapeutics

6. Janus kinase (JAK) Inhibitor Pipeline: Late Stage Products (Pre-registration)

7. Janus kinase (JAK) Inhibitor Pipeline: Late Stage Products (Phase III)

8. Janus kinase (JAK) Inhibitor Pipeline: Mid Stage Products (Phase II)

9. Janus kinase (JAK) Inhibitor Pipeline: Early Stage Products (Phase I)

10. Janus kinase (JAK) Inhibitor Pipeline Therapeutic Assessment

11. Inactive Products in the Janus kinase (JAK) Inhibitor Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Janus kinase (JAK) Inhibitor Companies

14. Key Products in the Janus kinase (JAK) Inhibitor Pipeline

15. Unmet Needs

16. Janus kinase (JAK) Inhibitor Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-competitive-landscape

Leave a Reply

Your email address will not be published. Required fields are marked *